Evidence map›Paper›PMID 33037990›Full record

ArticleInternational journal of hematology2021

Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.

Naoki Takezako, Hirohiko Shibayama, Hiroshi Handa, Shotaro Hagiwara, Shuji Ozaki, Kenshi Suzuki, Hiroshi Kosugi, Masaki Ri, Isamu Sugiura, Ilseung Choi and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 1 country.

Naoki TakezakoNational Hospital Organization Disaster Medical Center, 3256 Midori, Tachikawa, Tokyo, 190-0014, Japan. ntakezak@tdmc.hosp.go.jp.
Hirohiko ShibayamaOsaka University Graduate School of Medicine, Suita, Japan.
Hiroshi HandaGunma University Graduate School, Maebashi, Japan.
Shotaro HagiwaraTokyo Women's University, Tokyo, Japan.
Shuji OzakiTokushima Prefectural Central Hospital, Tokushima, Japan.
Kenshi SuzukiJapanese Red Cross Medical Center, Tokyo, Japan.
Hiroshi KosugiOgaki Municipal Hospital, Ogaki, Japan.
Masaki RiNagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Isamu SugiuraToyohashi Municipal Hospital, Toyohashi, Japan.
Ilseung ChoiNational Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Toshihiro MiyamotoKyushu University Hospital, Fukuoka, Japan.
Shinsuke IidaNagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Nagoya City University · JPGunma University · JPJapanese Red Cross Medical Center · JPKyushu University Hospital · JPNational Hospital Organization · JPNational Hospital Organization Kyushu Cancer Center · JPOgaki Municipal Hospital · JPOsaka University · JPTokushima Prefectural Central Hospital · JPToyohashi Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A.R.R.O.W. evaluated the superiority of once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase III as TopicDrug Administration ScheduleDrug Resistance, NeoplasmFemaleHumansJapanMaleMiddle AgedMultiple MyelomaNeoplasm GradingAntineoplastic AgentscarfilzomibOligopeptidesProteasome InhibitorsCarfilzomibJapaneseKyprolisOnce-weeklyRelapsed and refractory multiple myeloma

Identifiers

PMID33037990
PMCPMC7547551
OpenAlexW3092154482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.